News Headlines Article

Roche to pay rich price for one-drug InterMune
San Francisco Business Times

Roche — the Swiss parent of Genentech Inc. — will buy Brisbane’s InterMune Inc. for $8.3 billion, according to a deal disclosed Sunday.

The $74-per-share, all-cash deal really is no surprise. Rumors of a buyout by any one of a handful of Big Pharma players surged as InterMune’s experimental treatment for a fatal lung-scarring disease neared an approval-decision date with the Food and Drug Administration.

Commands